Literature DB >> 16161050

Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue.

Walter Meinl1, Ulrike Pabel, Mandy Osterloh-Quiroz, Jan G Hengstler, Hansruedi Glatt.   

Abstract

Use of herbal preparations containing Aristolochia species has led to progressive nephropathy and urothelial cancer in humans. Analysis of DNA adducts formed in human target tissues and studies in animal models have pointed out a major role of the secondary plant metabolites, aristolochic acids, in these effects. Only a minority of the users of Aristolochia-containing products developed nephropathy and cancer, suggesting differences in individual susceptibility. Differences in metabolic activation and inactivation frequently affect the susceptibility towards chemicals. Others have shown that the activation of aristolochic acids to DNA-reactive and mutagenic metabolites requires reduction of their aryl nitro group. The biological activity of numerous nitro- and aminoarenes, after appropriate phase I metabolism, is strongly enhanced in the presence of acetyltransferases or sulphotransferases (SULTs). In the present study, we demonstrate that expression of human SULTs in bacterial and mammalian target cells reinforces the mutagenic activity of aristolochic acids. Using Salmonella typhimurium TA1538 as the recipient organism, we identified the expression of all 12 human SULT forms. SULT1A1 led to the strongest increase in the mutagenicity of aristolochic acids. Some activation was also observed with SULT1B1, but not with the remaining forms. The role of SULT1A1 in the activation of aristolochic acids was corroborated using S. typhimurium TA100- and Chinese hamster V79-derived target cells engineered for expression of human SULT1A1 when compared with control cells. Furthermore, pentachlorophenol, an inhibitor of SULT1A1, strongly reduced the mutagenic effect of aristolochic acids in V79-hCYP2E1-hSULT1A1 cells. Moreover, we demonstrate that SULT1A1 and SULT1B1 are expressed in human kidney using immunoblot analysis, but their levels are substantially lower than in liver. Finally, we discuss the possibility that reactive sulphuric acid conjugates produced in other tissues are transferred to kidney and ureter. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16161050     DOI: 10.1002/ijc.21480

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

2.  The influence of the SULT1A status - wild-type, knockout or humanized - on the DNA adduct formation by methyleugenol in extrahepatic tissues of mice.

Authors:  K Herrmann; W Engst; S Florian; A Lampen; W Meinl; H R Glatt
Journal:  Toxicol Res (Camb)       Date:  2016-02-12       Impact factor: 3.524

3.  Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity.

Authors:  Shih-Yu Chang; Elijah J Weber; Viktoriya S Sidorenko; Alenka Chapron; Catherine K Yeung; Chunying Gao; Qingcheng Mao; Danny Shen; Joanne Wang; Thomas A Rosenquist; Kathleen G Dickman; Thomas Neumann; Arthur P Grollman; Edward J Kelly; Jonathan Himmelfarb; David L Eaton
Journal:  JCI Insight       Date:  2017-11-16

4.  Genetic loci that affect aristolochic acid-induced nephrotoxicity in the mouse.

Authors:  Thomas A Rosenquist
Journal:  Am J Physiol Renal Physiol       Date:  2011-03-23

5.  Identification of a reduction product of aristolochic acid: implications for the metabolic activation of carcinogenic aristolochic acid.

Authors:  Horacio A Priestap; Carlos de los Santos; J Martin E Quirke
Journal:  J Nat Prod       Date:  2010-12-08       Impact factor: 4.050

6.  Identification and localization of soluble sulfotransferases in the human gastrointestinal tract.

Authors:  Wera Teubner; Walter Meinl; Simone Florian; Michael Kretzschmar; Hansruedi Glatt
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

7.  Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse.

Authors:  Thomas A Rosenquist; Heidi J Einolf; Kathleen G Dickman; Lai Wang; Amanda Smith; Arthur P Grollman
Journal:  Drug Metab Dispos       Date:  2010-02-17       Impact factor: 3.922

8.  The gate that governs sulfotransferase selectivity.

Authors:  Ian Cook; Ting Wang; Steven C Almo; Jungwook Kim; Charles N Falany; Thomas S Leyh
Journal:  Biochemistry       Date:  2012-12-28       Impact factor: 3.162

9.  Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and N-hydroxyaristolactam I in human cells.

Authors:  Keiji Hashimoto; Irina N Zaitseva; Radha Bonala; Sivaprasad Attaluri; Katherine Ozga; Charles R Iden; Francis Johnson; Masaaki Moriya; Arthur P Grollman; Viktoriya S Sidorenko
Journal:  Carcinogenesis       Date:  2016-04-18       Impact factor: 4.944

10.  In Silico Prediction of Human Sulfotransferase 1E1 Activity Guided by Pharmacophores from Molecular Dynamics Simulations.

Authors:  Christin Rakers; Fabian Schumacher; Walter Meinl; Hansruedi Glatt; Burkhard Kleuser; Gerhard Wolber
Journal:  J Biol Chem       Date:  2015-11-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.